Coherus Oncology, Inc. (CHRS) 10-Year Financial Performance & Capital Metrics

CHRS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutCoherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.Show more

Revenue $267M +3.8%
EBITDA -$106M +46.6%
Net Income $29M +112.0%
EPS (Diluted) 0.25 +109.9%
Gross Margin 55.97% +46.5%
EBITDA Margin -39.85% +48.6%
Operating Margin -41.83% +47.0%
Net Margin 10.68% +111.5%
ROE -
ROIC -85.26% -29.8%
Debt/Equity -
Interest Coverage -4.11 +18.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Profits declining 20.5% over 5 years
✗Negative free cash flow
✗Sales declining 5.6% over 5 years
✗Shares diluted 21.9% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.98%

5Y-5.6%

3Y-6.5%

TTM-63.6%

Profit (Net Income) CAGR

10Y-

5Y-20.51%

3Y-

TTM34538%

EPS CAGR

10Y-

5Y-27.29%

3Y-

TTM-1614.9%

ROCE

10Y Avg-79.17%

5Y Avg-36.75%

3Y Avg-57.23%

Latest-48.2%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	30.04M	190.11M	1.56M	1.56M	356.07M	475.82M	326.55M	211.04M	257.24M	266.96M
Revenue Growth %	-0.03%	5.33%	-0.99%	0%	227.84%	0.34%	-0.31%	-0.35%	0.22%	0.04%
Cost of Goods Sold+	212.68M	254.44M	160.53M	3.23M	17.08M	37.67M	57.59M	70.08M	158.99M	117.55M
COGS % of Revenue	7.08%	1.34%	103.17%	2.08%	0.05%	0.08%	0.18%	0.33%	0.62%	0.44%
Gross Profit+	-182.64M	-64.33M	-158.97M	-1.68M	338.99M	438.16M	268.96M	140.96M	98.25M	149.41M
Gross Margin %	-6.08%	-0.34%	-102.17%	-1.08%	0.95%	0.92%	0.82%	0.67%	0.38%	0.56%
Gross Profit Growth %	-2.88%	0.65%	-1.47%	0.99%	202.9%	0.29%	-0.39%	-0.48%	-0.3%	0.52%
Operating Expenses+	249.11M	306.04M	233.69M	204.42M	231.22M	281.84M	532.82M	397.84M	301.45M	261.07M
OpEx % of Revenue	8.29%	1.61%	150.19%	131.37%	0.65%	0.59%	1.63%	1.89%	1.17%	0.98%
Selling, General & Admin	36.05M	51.6M	71.3M	94.18M	137.04M	139.08M	169.71M	198.48M	185.62M	150.44M
SG&A % of Revenue	1.2%	0.27%	45.82%	60.53%	0.38%	0.29%	0.52%	0.94%	0.72%	0.56%
Research & Development	213.06M	254.44M	162.39M	110.24M	94.19M	142.76M	363.11M	199.36M	109.44M	93.34M
R&D % of Revenue	7.09%	1.34%	104.36%	70.85%	0.26%	0.3%	1.11%	0.94%	0.43%	0.35%
Other Operating Expenses	-4.84M	-3.88M	3.4M	4.69M	0	0	0	0	6.4M	17.3M
Operating Income+	-219.07M	-115.93M	-232.14M	-204.42M	107.77M	156.32M	-263.86M	-256.88M	-203.2M	-111.67M
Operating Margin %	-7.29%	-0.61%	-149.19%	-131.37%	0.3%	0.33%	-0.81%	-1.22%	-0.79%	-0.42%
Operating Income Growth %	-2.39%	0.47%	-1%	0.12%	1.53%	0.45%	-2.69%	0.03%	0.21%	0.45%
EBITDA+	-217.2M	-112.94M	-228.74M	-201.18M	111.03M	161.29M	-260.4M	-253.18M	-199.41M	-106.39M
EBITDA Margin %	-7.23%	-0.59%	-147%	-129.29%	0.31%	0.34%	-0.8%	-1.2%	-0.78%	-0.4%
EBITDA Growth %	-2.39%	0.48%	-1.03%	0.12%	1.55%	0.45%	-2.61%	0.03%	0.21%	0.47%
D&A (Non-Cash Add-back)	1.87M	3M	3.4M	3.23M	3.26M	4.97M	3.45M	3.7M	3.79M	5.28M
EBIT	-223.91M	-119.81M	-228.73M	-200.56M	107.77M	156.87M	-264.14M	-259.28M	-197.73M	55.66M
Net Interest Income+	-33K	-7.98M	-9.55M	0	-17.6M	-21.17M	-22.96M	-32.47M	-40.54M	-27.16M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	33K	7.98M	9.55M	9.68M	17.6M	21.17M	22.96M	32.47M	40.54M	27.16M
Other Income/Expense	-4.87M	-11.86M	-6.15M	-4.99M	-14.99M	-20.61M	-23.24M	-34.87M	-35.07M	140.17M
Pretax Income+	-223.94M	-127.79M	-238.29M	-209.41M	92.78M	135.71M	-287.1M	-291.75M	-238.27M	28.51M
Pretax Margin %	-7.45%	-0.67%	-153.14%	-134.58%	0.26%	0.29%	-0.88%	-1.38%	-0.93%	0.11%
Income Tax+	0	656K	0	0	2.94M	3.46M	0	0	-380K	0
Effective Tax Rate %	1%	1%	1%	1%	0.97%	0.97%	1%	1%	1%	1%
Net Income+	-223.26M	-127.34M	-238.17M	-209.34M	89.83M	132.24M	-287.1M	-291.75M	-237.89M	28.51M
Net Margin %	-7.43%	-0.67%	-153.07%	-134.54%	0.25%	0.28%	-0.88%	-1.38%	-0.92%	0.11%
Net Income Growth %	-1.56%	0.43%	-0.87%	0.12%	1.43%	0.47%	-3.17%	-0.02%	0.18%	1.12%
Net Income (Continuing)	-223.94M	-127.79M	-238.29M	-209.41M	89.83M	132.24M	-287.1M	-291.75M	-237.89M	28.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-722K	-1.17M	-1.29M	0	0	0	0	0	0	0
EPS (Diluted)+	-6.01	-3.04	-4.48	-3.22	1.23	1.62	-3.81	-3.76	-2.53	0.25
EPS Growth %	0.44%	0.49%	-0.47%	0.28%	1.38%	0.32%	-3.35%	0.01%	0.33%	1.1%
EPS (Basic)	-6.01	-3.04	-4.48	-3.22	1.29	1.85	-3.81	-3.76	-2.53	0.25
Diluted Shares Outstanding	37.12M	41.91M	53.13M	65.03M	73.19M	83.49M	75.45M	77.63M	94.16M	114.83M
Basic Shares Outstanding	37.12M	41.91M	53.13M	65.01M	69.68M	71.41M	75.45M	77.63M	94.16M	114.55M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	158.23M	124.95M	126.91M	72.36M	343.01M	767.48M	602.32M	381.23M	475.63M	341.58M
Cash & Short-Term Investments	158.23M	124.95M	126.91M	72.36M	177.67M	541.16M	417.19M	191.68M	117.75M	125.99M
Cash Only	158.23M	124.95M	126.91M	72.36M	177.67M	541.16M	417.19M	63.55M	102.89M	125.99M
Short-Term Investments	0	0	0	0	0	0	0	128.13M	14.86M	0
Accounts Receivable	1.56M	1.86M	0	0	141.99M	157.05M	123.02M	109.96M	260.52M	122.33M
Days Sales Outstanding	18.95	3.57	-	-	145.55	120.47	137.51	190.18	369.65	167.26
Inventory	-4.36M	-4.84M	0	1.66M	9.81M	44.23M	37.64M	38.79M	62.6M	70.09M
Days Inventory Outstanding	-	-	-	187.18	209.6	428.63	238.57	202.03	143.72	217.64
Other Current Assets	2.86M	3.05M	202K	50K	0	0	10.8M	22.92M	11.1M	11.53M
Total Non-Current Assets+	54.16M	53.54M	35.7M	27.11M	65.92M	74.17M	77.01M	99.61M	153.97M	106.95M
Property, Plant & Equipment	10.5M	10.77M	12.77M	6.66M	16.49M	10.11M	7.81M	8.75M	5.12M	2.84M
Fixed Asset Turnover	2.86x	17.65x	0.12x	0.23x	21.59x	47.07x	41.80x	24.11x	50.25x	94.10x
Goodwill	943K	943K	943K	943K	943K	943K	943K	943K	943K	0
Intangible Assets	2.62M	2.62M	2.62M	2.62M	2.62M	2.62M	2.62M	4.99M	70.73M	53.65M
Long-Term Investments	785K	785K	785K	785K	0	0	0	0	0	0
Other Non-Current Assets	40.09M	39.2M	19.36M	16.89M	45.87M	60.5M	65.64M	84.93M	77.18M	50.47M
Total Assets+	212.38M	178.49M	162.61M	99.47M	408.93M	841.65M	679.33M	480.85M	629.6M	448.53M
Asset Turnover	0.14x	1.07x	0.01x	0.02x	0.87x	0.57x	0.48x	0.44x	0.41x	0.60x
Asset Growth %	0.13%	-0.16%	-0.09%	-0.39%	3.11%	1.06%	-0.19%	-0.29%	0.31%	-0.29%
Total Current Liabilities+	106.02M	56.38M	28.39M	33.26M	114.97M	145.65M	165.33M	138.69M	331.77M	282.98M
Accounts Payable	29.5M	20.58M	15.71M	15.29M	25.98M	15.2M	16.16M	11.53M	35.22M	28.46M
Days Payables Outstanding	50.62	29.53	35.73	1.73K	555.37	147.3	102.41	60.03	80.85	88.36
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	20.91M	26.89M	3.63M	419K	20.61M	22.24M	22.01M	22.61M	21.52M	33.11M
Current Ratio	1.49x	2.22x	4.47x	2.18x	2.98x	5.27x	3.64x	2.75x	1.43x	1.21x
Quick Ratio	1.53x	2.30x	4.47x	2.13x	2.90x	4.97x	3.42x	2.47x	1.24x	0.96x
Cash Conversion Cycle	-	-	-	-	-200.21	401.79	273.66	332.18	432.52	296.55
Total Non-Current Liabilities+	219.31M	159.13M	132.08M	138.06M	188.74M	415.02M	416.28M	479.57M	491.26M	297.54M
Long-Term Debt	0	100.26M	101.61M	103.09M	178.39M	404.02M	408.28M	471.06M	473.37M	264.93M
Capital Lease Obligations	0	0	0	0	10.26M	9.95M	7.25M	5.05M	5.33M	3.29M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	1.1M	1.1M
Other Non-Current Liabilities	67.96M	1.83M	2.07M	1.71M	102K	1.05M	750K	3.47M	11.46M	28.23M
Total Liabilities	219.31M	159.13M	132.08M	138.06M	303.71M	560.67M	581.61M	618.26M	823.03M	580.52M
Total Debt+	0	100.26M	101.41M	103.09M	188.64M	417.1M	419.02M	480.42M	480.84M	269.9M
Net Debt	-158.23M	-24.69M	-25.5M	30.74M	10.97M	-124.06M	1.83M	416.88M	377.95M	143.92M
Debt / Equity	-	5.51x	3.47x	-	1.79x	1.48x	4.29x	-	-	-
Debt / EBITDA	-	-	-	-	1.70x	2.59x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	0.10x	-0.77x	-	-	-	-
Interest Coverage	-6638.39x	-14.53x	-24.30x	-21.11x	6.12x	7.39x	-11.49x	-7.91x	-5.01x	-4.11x
Total Equity+	-7.65M	18.18M	29.25M	-38.59M	105.21M	280.97M	97.73M	-137.42M	-193.43M	-131.99M
Equity Growth %	-1.11%	3.38%	0.61%	-2.32%	3.73%	1.67%	-0.65%	-2.41%	-0.41%	0.32%
Book Value per Share	-0.21	0.43	0.55	-0.59	1.44	3.37	1.30	-1.77	-2.05	-1.15
Total Shareholders' Equity	-6.93M	19.35M	30.54M	-38.59M	105.21M	280.97M	97.73M	-137.42M	-193.43M	-131.99M
Common Stock	4K	5K	6K	7K	7K	7K	7K	8K	11K	12K
Retained Earnings	-409.99M	-537.32M	-775.49M	-984.83M	-895M	-762.75M	-1.05B	-1.34B	-1.58B	-1.55B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-401K	-630K	-750K	-282K	-558K	-270K	-270K	-249K	-248K	-275K
Minority Interest	-722K	-1.17M	-1.29M	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-107.99M	-252.54M	-200.29M	-159.27M	28.36M	154.15M	-37.43M	-241.12M	-174.88M	-20.44M
Operating CF Margin %	-3.59%	-1.33%	-128.72%	-102.36%	0.08%	0.32%	-0.11%	-1.14%	-0.68%	-0.08%
Operating CF Growth %	-3.51%	-1.34%	0.21%	0.2%	1.18%	4.44%	-1.24%	-5.44%	0.27%	0.88%
Net Income	-223.94M	-127.79M	-238.29M	-209.41M	89.83M	132.24M	-287.1M	-291.75M	-237.89M	28.51M
Depreciation & Amortization	1.87M	3M	3.4M	3.23M	3.26M	2.89M	3.45M	3.7M	3.79M	5.28M
Stock-Based Compensation	16.72M	27.42M	36.06M	34.8M	33.59M	38.16M	51.36M	50.74M	0	27.8M
Deferred Taxes	1.68M	-1.31M	453K	3.56M	-55K	0	9.44M	0	0	0
Other Non-Cash Items	4.56M	5.35M	3.22M	-1.75M	15.65M	15.5M	143.05M	75.45M	96.04M	-137.92M
Working Capital Changes	91.11M	-159.21M	-5.13M	10.3M	-113.93M	-34.65M	42.36M	-79.26M	-36.83M	55.89M
Change in Receivables	857K	-299K	1.86M	8.28M	-141.99M	-15.22M	34.06M	13.05M	-150.68M	149.35M
Change in Inventory	-1.27M	8.26M	-148K	-5.48M	-48.18M	-38.36M	-6.25M	-47.35M	-46.73M	-31.95M
Change in Payables	19.93M	-7.64M	-4.45M	-534K	9.89M	-9.82M	874K	-4.55M	23.76M	-3.94M
Cash from Investing+	-6.95M	-6.51M	-4.42M	-1.19M	-12.73M	-14.4M	-138.41M	-166.85M	144.64M	230.32M
Capital Expenditures	-6.16M	-6.51M	-4.57M	-789K	-12.9M	-7.23M	-1.29M	-2.04M	-286K	0
CapEx % of Revenue	0.21%	0.03%	2.94%	0.51%	0.04%	0.02%	0%	0.01%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-785K	-6.51M	156K	301K	-1.66M	-7.33M	-137.29M	-37.43M	5.95M	215.43M
Cash from Financing+	122.69M	226.18M	206.79M	105.42M	89.37M	223.95M	51.88M	54.33M	69.6M	-186.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-111K	2.57M	482K	3.67M	8.26M	1.79M	54.3M	-1.96M	-4.62M	34.98M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-114.15M	-259.06M	-204.86M	-160.06M	15.46M	146.91M	-38.72M	-243.16M	-175.17M	-20.44M
FCF Margin %	-3.8%	-1.36%	-131.66%	-102.86%	0.04%	0.31%	-0.12%	-1.15%	-0.68%	-0.08%
FCF Growth %	-3.26%	-1.27%	0.21%	0.22%	1.1%	8.5%	-1.26%	-5.28%	0.28%	0.88%
FCF per Share	-3.08	-6.18	-3.86	-2.46	0.21	1.76	-0.51	-3.13	-1.86	-0.18
FCF Conversion (FCF/Net Income)	0.48x	1.98x	0.84x	0.76x	0.32x	1.17x	0.13x	0.83x	0.74x	-0.72x
Interest Paid	0	0	0	0	15.26M	16.96M	18.68M	34.88M	0	0
Taxes Paid	0	0	0	0	1.73M	3.95M	1.22M	40K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-756.02%	-2418.56%	-1004.36%	-	269.68%	68.49%	-151.62%	-	-	-
Return on Invested Capital (ROIC)	-	-	-	-	149.22%	85.86%	-154.32%	-101.66%	-65.69%	-85.26%
Gross Margin	-607.97%	-33.84%	-10216.9%	-107.9%	95.2%	92.08%	82.36%	66.79%	38.19%	55.97%
Net Margin	-743.18%	-66.98%	-15306.56%	-13453.66%	25.23%	27.79%	-87.92%	-138.24%	-92.48%	10.68%
Debt / Equity	-	5.51x	3.47x	-	1.79x	1.48x	4.29x	-	-	-
Interest Coverage	-6638.39x	-14.53x	-24.30x	-21.11x	6.12x	7.39x	-11.49x	-7.91x	-5.01x	-4.11x
FCF Conversion	0.48x	1.98x	0.84x	0.76x	0.32x	1.17x	0.13x	0.83x	0.74x	-0.72x
Revenue Growth	-3.42%	532.82%	-99.18%	0%	22783.74%	33.63%	-31.37%	-35.37%	21.89%	3.78%

Revenue by Segment

	2014	2015	2016	2017	2019	2021	2022	2023	2024
Product	-	-	-	-	356.07M	-	-	-	259.7M
Product Growth	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	-	-	7.26M
Product and Service, Other Growth	-	-	-	-	-	-	-	-	-
Product Revenue	-	-	-	-	-	326.6M	210.76M	256.58M	-
Product Revenue Growth	-	-	-	-	-	-	-35.47%	21.74%	-
Other	-	-	-	-	-	-	282K	664K	-
Other Growth	-	-	-	-	-	-	-	135.46%	-
License And Service	-	-	-	-	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2016	2017	2019	2021	2022	2023	2024
UNITED STATES	-	-	188.29M	-	356.07M	-	-	-	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	-
Non Us	-	2.24M	1.81M	1.56M	-	-	-	-	-
Non Us Growth	-	-	-18.98%	-14.22%	-	-	-	-	-
U S	28.48M	27.8M	-	-	-	-	-	-	-
U S Growth	-	-2.38%	-	-	-	-	-	-	-
Foreign Countries	2.63M	-	-	-	-	-	-	-	-
Foreign Countries Growth	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Coherus Oncology, Inc. (CHRS) has a price-to-earnings (P/E) ratio of 6.6x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Coherus Oncology, Inc. (CHRS) reported $83.6M in revenue for fiscal year 2024. This represents a 4301% increase from $1.9M in 2012.

Coherus Oncology, Inc. (CHRS) grew revenue by 3.8% over the past year. Growth has been modest.

Yes, Coherus Oncology, Inc. (CHRS) is profitable, generating $155.0M in net income for fiscal year 2024 (10.7% net margin).

Dividend & Returns

Coherus Oncology, Inc. (CHRS) had negative free cash flow of $90.2M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Coherus Oncology, Inc. (CHRS) 10-Year Financial Performance & Capital Metrics

CHRS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

Revenue $267M +3.8%
EBITDA -$106M +46.6%
Net Income $29M +112.0%
EPS (Diluted) 0.25 +109.9%
Gross Margin 55.97% +46.5%
EBITDA Margin -39.85% +48.6%
Operating Margin -41.83% +47.0%
Net Margin 10.68% +111.5%
ROE -
ROIC -85.26% -29.8%
Debt/Equity -
Interest Coverage -4.11 +18.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 88 (top 12%)

✗Weaknesses

✗Profits declining 20.5% over 5 years
✗Negative free cash flow
✗Sales declining 5.6% over 5 years
✗Shares diluted 21.9% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.98%

5Y-5.6%

3Y-6.5%

TTM-63.6%

Profit (Net Income) CAGR

10Y-

5Y-20.51%

3Y-

TTM34538%

EPS CAGR

10Y-

5Y-27.29%

3Y-

TTM-1614.9%

ROCE

10Y Avg-79.17%

5Y Avg-36.75%

3Y Avg-57.23%

Latest-48.2%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	30.04M	190.11M	1.56M	1.56M	356.07M	475.82M	326.55M	211.04M	257.24M	266.96M
Revenue Growth %	-0.03%	5.33%	-0.99%	0%	227.84%	0.34%	-0.31%	-0.35%	0.22%	0.04%
Cost of Goods Sold+	212.68M	254.44M	160.53M	3.23M	17.08M	37.67M	57.59M	70.08M	158.99M	117.55M
COGS % of Revenue	7.08%	1.34%	103.17%	2.08%	0.05%	0.08%	0.18%	0.33%	0.62%	0.44%
Gross Profit+	-182.64M	-64.33M	-158.97M	-1.68M	338.99M	438.16M	268.96M	140.96M	98.25M	149.41M
Gross Margin %	-6.08%	-0.34%	-102.17%	-1.08%	0.95%	0.92%	0.82%	0.67%	0.38%	0.56%
Gross Profit Growth %	-2.88%	0.65%	-1.47%	0.99%	202.9%	0.29%	-0.39%	-0.48%	-0.3%	0.52%
Operating Expenses+	249.11M	306.04M	233.69M	204.42M	231.22M	281.84M	532.82M	397.84M	301.45M	261.07M
OpEx % of Revenue	8.29%	1.61%	150.19%	131.37%	0.65%	0.59%	1.63%	1.89%	1.17%	0.98%
Selling, General & Admin	36.05M	51.6M	71.3M	94.18M	137.04M	139.08M	169.71M	198.48M	185.62M	150.44M
SG&A % of Revenue	1.2%	0.27%	45.82%	60.53%	0.38%	0.29%	0.52%	0.94%	0.72%	0.56%
Research & Development	213.06M	254.44M	162.39M	110.24M	94.19M	142.76M	363.11M	199.36M	109.44M	93.34M
R&D % of Revenue	7.09%	1.34%	104.36%	70.85%	0.26%	0.3%	1.11%	0.94%	0.43%	0.35%
Other Operating Expenses	-4.84M	-3.88M	3.4M	4.69M	0	0	0	0	6.4M	17.3M
Operating Income+	-219.07M	-115.93M	-232.14M	-204.42M	107.77M	156.32M	-263.86M	-256.88M	-203.2M	-111.67M
Operating Margin %	-7.29%	-0.61%	-149.19%	-131.37%	0.3%	0.33%	-0.81%	-1.22%	-0.79%	-0.42%
Operating Income Growth %	-2.39%	0.47%	-1%	0.12%	1.53%	0.45%	-2.69%	0.03%	0.21%	0.45%
EBITDA+	-217.2M	-112.94M	-228.74M	-201.18M	111.03M	161.29M	-260.4M	-253.18M	-199.41M	-106.39M
EBITDA Margin %	-7.23%	-0.59%	-147%	-129.29%	0.31%	0.34%	-0.8%	-1.2%	-0.78%	-0.4%
EBITDA Growth %	-2.39%	0.48%	-1.03%	0.12%	1.55%	0.45%	-2.61%	0.03%	0.21%	0.47%
D&A (Non-Cash Add-back)	1.87M	3M	3.4M	3.23M	3.26M	4.97M	3.45M	3.7M	3.79M	5.28M
EBIT	-223.91M	-119.81M	-228.73M	-200.56M	107.77M	156.87M	-264.14M	-259.28M	-197.73M	55.66M
Net Interest Income+	-33K	-7.98M	-9.55M	0	-17.6M	-21.17M	-22.96M	-32.47M	-40.54M	-27.16M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	33K	7.98M	9.55M	9.68M	17.6M	21.17M	22.96M	32.47M	40.54M	27.16M
Other Income/Expense	-4.87M	-11.86M	-6.15M	-4.99M	-14.99M	-20.61M	-23.24M	-34.87M	-35.07M	140.17M
Pretax Income+	-223.94M	-127.79M	-238.29M	-209.41M	92.78M	135.71M	-287.1M	-291.75M	-238.27M	28.51M
Pretax Margin %	-7.45%	-0.67%	-153.14%	-134.58%	0.26%	0.29%	-0.88%	-1.38%	-0.93%	0.11%
Income Tax+	0	656K	0	0	2.94M	3.46M	0	0	-380K	0
Effective Tax Rate %	1%	1%	1%	1%	0.97%	0.97%	1%	1%	1%	1%
Net Income+	-223.26M	-127.34M	-238.17M	-209.34M	89.83M	132.24M	-287.1M	-291.75M	-237.89M	28.51M
Net Margin %	-7.43%	-0.67%	-153.07%	-134.54%	0.25%	0.28%	-0.88%	-1.38%	-0.92%	0.11%
Net Income Growth %	-1.56%	0.43%	-0.87%	0.12%	1.43%	0.47%	-3.17%	-0.02%	0.18%	1.12%
Net Income (Continuing)	-223.94M	-127.79M	-238.29M	-209.41M	89.83M	132.24M	-287.1M	-291.75M	-237.89M	28.51M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-722K	-1.17M	-1.29M	0	0	0	0	0	0	0
EPS (Diluted)+	-6.01	-3.04	-4.48	-3.22	1.23	1.62	-3.81	-3.76	-2.53	0.25
EPS Growth %	0.44%	0.49%	-0.47%	0.28%	1.38%	0.32%	-3.35%	0.01%	0.33%	1.1%
EPS (Basic)	-6.01	-3.04	-4.48	-3.22	1.29	1.85	-3.81	-3.76	-2.53	0.25
Diluted Shares Outstanding	37.12M	41.91M	53.13M	65.03M	73.19M	83.49M	75.45M	77.63M	94.16M	114.83M
Basic Shares Outstanding	37.12M	41.91M	53.13M	65.01M	69.68M	71.41M	75.45M	77.63M	94.16M	114.55M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	158.23M	124.95M	126.91M	72.36M	343.01M	767.48M	602.32M	381.23M	475.63M	341.58M
Cash & Short-Term Investments	158.23M	124.95M	126.91M	72.36M	177.67M	541.16M	417.19M	191.68M	117.75M	125.99M
Cash Only	158.23M	124.95M	126.91M	72.36M	177.67M	541.16M	417.19M	63.55M	102.89M	125.99M
Short-Term Investments	0	0	0	0	0	0	0	128.13M	14.86M	0
Accounts Receivable	1.56M	1.86M	0	0	141.99M	157.05M	123.02M	109.96M	260.52M	122.33M
Days Sales Outstanding	18.95	3.57	-	-	145.55	120.47	137.51	190.18	369.65	167.26
Inventory	-4.36M	-4.84M	0	1.66M	9.81M	44.23M	37.64M	38.79M	62.6M	70.09M
Days Inventory Outstanding	-	-	-	187.18	209.6	428.63	238.57	202.03	143.72	217.64
Other Current Assets	2.86M	3.05M	202K	50K	0	0	10.8M	22.92M	11.1M	11.53M
Total Non-Current Assets+	54.16M	53.54M	35.7M	27.11M	65.92M	74.17M	77.01M	99.61M	153.97M	106.95M
Property, Plant & Equipment	10.5M	10.77M	12.77M	6.66M	16.49M	10.11M	7.81M	8.75M	5.12M	2.84M
Fixed Asset Turnover	2.86x	17.65x	0.12x	0.23x	21.59x	47.07x	41.80x	24.11x	50.25x	94.10x
Goodwill	943K	943K	943K	943K	943K	943K	943K	943K	943K	0
Intangible Assets	2.62M	2.62M	2.62M	2.62M	2.62M	2.62M	2.62M	4.99M	70.73M	53.65M
Long-Term Investments	785K	785K	785K	785K	0	0	0	0	0	0
Other Non-Current Assets	40.09M	39.2M	19.36M	16.89M	45.87M	60.5M	65.64M	84.93M	77.18M	50.47M
Total Assets+	212.38M	178.49M	162.61M	99.47M	408.93M	841.65M	679.33M	480.85M	629.6M	448.53M
Asset Turnover	0.14x	1.07x	0.01x	0.02x	0.87x	0.57x	0.48x	0.44x	0.41x	0.60x
Asset Growth %	0.13%	-0.16%	-0.09%	-0.39%	3.11%	1.06%	-0.19%	-0.29%	0.31%	-0.29%
Total Current Liabilities+	106.02M	56.38M	28.39M	33.26M	114.97M	145.65M	165.33M	138.69M	331.77M	282.98M
Accounts Payable	29.5M	20.58M	15.71M	15.29M	25.98M	15.2M	16.16M	11.53M	35.22M	28.46M
Days Payables Outstanding	50.62	29.53	35.73	1.73K	555.37	147.3	102.41	60.03	80.85	88.36
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	1000K	1000K	1000K	0	0	0	0	0	0	0
Other Current Liabilities	20.91M	26.89M	3.63M	419K	20.61M	22.24M	22.01M	22.61M	21.52M	33.11M
Current Ratio	1.49x	2.22x	4.47x	2.18x	2.98x	5.27x	3.64x	2.75x	1.43x	1.21x
Quick Ratio	1.53x	2.30x	4.47x	2.13x	2.90x	4.97x	3.42x	2.47x	1.24x	0.96x
Cash Conversion Cycle	-	-	-	-	-200.21	401.79	273.66	332.18	432.52	296.55
Total Non-Current Liabilities+	219.31M	159.13M	132.08M	138.06M	188.74M	415.02M	416.28M	479.57M	491.26M	297.54M
Long-Term Debt	0	100.26M	101.61M	103.09M	178.39M	404.02M	408.28M	471.06M	473.37M	264.93M
Capital Lease Obligations	0	0	0	0	10.26M	9.95M	7.25M	5.05M	5.33M	3.29M
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	1.1M	1.1M
Other Non-Current Liabilities	67.96M	1.83M	2.07M	1.71M	102K	1.05M	750K	3.47M	11.46M	28.23M
Total Liabilities	219.31M	159.13M	132.08M	138.06M	303.71M	560.67M	581.61M	618.26M	823.03M	580.52M
Total Debt+	0	100.26M	101.41M	103.09M	188.64M	417.1M	419.02M	480.42M	480.84M	269.9M
Net Debt	-158.23M	-24.69M	-25.5M	30.74M	10.97M	-124.06M	1.83M	416.88M	377.95M	143.92M
Debt / Equity	-	5.51x	3.47x	-	1.79x	1.48x	4.29x	-	-	-
Debt / EBITDA	-	-	-	-	1.70x	2.59x	-	-	-	-
Net Debt / EBITDA	-	-	-	-	0.10x	-0.77x	-	-	-	-
Interest Coverage	-6638.39x	-14.53x	-24.30x	-21.11x	6.12x	7.39x	-11.49x	-7.91x	-5.01x	-4.11x
Total Equity+	-7.65M	18.18M	29.25M	-38.59M	105.21M	280.97M	97.73M	-137.42M	-193.43M	-131.99M
Equity Growth %	-1.11%	3.38%	0.61%	-2.32%	3.73%	1.67%	-0.65%	-2.41%	-0.41%	0.32%
Book Value per Share	-0.21	0.43	0.55	-0.59	1.44	3.37	1.30	-1.77	-2.05	-1.15
Total Shareholders' Equity	-6.93M	19.35M	30.54M	-38.59M	105.21M	280.97M	97.73M	-137.42M	-193.43M	-131.99M
Common Stock	4K	5K	6K	7K	7K	7K	7K	8K	11K	12K
Retained Earnings	-409.99M	-537.32M	-775.49M	-984.83M	-895M	-762.75M	-1.05B	-1.34B	-1.58B	-1.55B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-401K	-630K	-750K	-282K	-558K	-270K	-270K	-249K	-248K	-275K
Minority Interest	-722K	-1.17M	-1.29M	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-107.99M	-252.54M	-200.29M	-159.27M	28.36M	154.15M	-37.43M	-241.12M	-174.88M	-20.44M
Operating CF Margin %	-3.59%	-1.33%	-128.72%	-102.36%	0.08%	0.32%	-0.11%	-1.14%	-0.68%	-0.08%
Operating CF Growth %	-3.51%	-1.34%	0.21%	0.2%	1.18%	4.44%	-1.24%	-5.44%	0.27%	0.88%
Net Income	-223.94M	-127.79M	-238.29M	-209.41M	89.83M	132.24M	-287.1M	-291.75M	-237.89M	28.51M
Depreciation & Amortization	1.87M	3M	3.4M	3.23M	3.26M	2.89M	3.45M	3.7M	3.79M	5.28M
Stock-Based Compensation	16.72M	27.42M	36.06M	34.8M	33.59M	38.16M	51.36M	50.74M	0	27.8M
Deferred Taxes	1.68M	-1.31M	453K	3.56M	-55K	0	9.44M	0	0	0
Other Non-Cash Items	4.56M	5.35M	3.22M	-1.75M	15.65M	15.5M	143.05M	75.45M	96.04M	-137.92M
Working Capital Changes	91.11M	-159.21M	-5.13M	10.3M	-113.93M	-34.65M	42.36M	-79.26M	-36.83M	55.89M
Change in Receivables	857K	-299K	1.86M	8.28M	-141.99M	-15.22M	34.06M	13.05M	-150.68M	149.35M
Change in Inventory	-1.27M	8.26M	-148K	-5.48M	-48.18M	-38.36M	-6.25M	-47.35M	-46.73M	-31.95M
Change in Payables	19.93M	-7.64M	-4.45M	-534K	9.89M	-9.82M	874K	-4.55M	23.76M	-3.94M
Cash from Investing+	-6.95M	-6.51M	-4.42M	-1.19M	-12.73M	-14.4M	-138.41M	-166.85M	144.64M	230.32M
Capital Expenditures	-6.16M	-6.51M	-4.57M	-789K	-12.9M	-7.23M	-1.29M	-2.04M	-286K	0
CapEx % of Revenue	0.21%	0.03%	2.94%	0.51%	0.04%	0.02%	0%	0.01%	0%	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-785K	-6.51M	156K	301K	-1.66M	-7.33M	-137.29M	-37.43M	5.95M	215.43M
Cash from Financing+	122.69M	226.18M	206.79M	105.42M	89.37M	223.95M	51.88M	54.33M	69.6M	-186.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-111K	2.57M	482K	3.67M	8.26M	1.79M	54.3M	-1.96M	-4.62M	34.98M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-114.15M	-259.06M	-204.86M	-160.06M	15.46M	146.91M	-38.72M	-243.16M	-175.17M	-20.44M
FCF Margin %	-3.8%	-1.36%	-131.66%	-102.86%	0.04%	0.31%	-0.12%	-1.15%	-0.68%	-0.08%
FCF Growth %	-3.26%	-1.27%	0.21%	0.22%	1.1%	8.5%	-1.26%	-5.28%	0.28%	0.88%
FCF per Share	-3.08	-6.18	-3.86	-2.46	0.21	1.76	-0.51	-3.13	-1.86	-0.18
FCF Conversion (FCF/Net Income)	0.48x	1.98x	0.84x	0.76x	0.32x	1.17x	0.13x	0.83x	0.74x	-0.72x
Interest Paid	0	0	0	0	15.26M	16.96M	18.68M	34.88M	0	0
Taxes Paid	0	0	0	0	1.73M	3.95M	1.22M	40K	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-756.02%	-2418.56%	-1004.36%	-	269.68%	68.49%	-151.62%	-	-	-
Return on Invested Capital (ROIC)	-	-	-	-	149.22%	85.86%	-154.32%	-101.66%	-65.69%	-85.26%
Gross Margin	-607.97%	-33.84%	-10216.9%	-107.9%	95.2%	92.08%	82.36%	66.79%	38.19%	55.97%
Net Margin	-743.18%	-66.98%	-15306.56%	-13453.66%	25.23%	27.79%	-87.92%	-138.24%	-92.48%	10.68%
Debt / Equity	-	5.51x	3.47x	-	1.79x	1.48x	4.29x	-	-	-
Interest Coverage	-6638.39x	-14.53x	-24.30x	-21.11x	6.12x	7.39x	-11.49x	-7.91x	-5.01x	-4.11x
FCF Conversion	0.48x	1.98x	0.84x	0.76x	0.32x	1.17x	0.13x	0.83x	0.74x	-0.72x
Revenue Growth	-3.42%	532.82%	-99.18%	0%	22783.74%	33.63%	-31.37%	-35.37%	21.89%	3.78%

Revenue by Segment

	2014	2015	2016	2017	2019	2021	2022	2023	2024
Product	-	-	-	-	356.07M	-	-	-	259.7M
Product Growth	-	-	-	-	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	-	-	7.26M
Product and Service, Other Growth	-	-	-	-	-	-	-	-	-
Product Revenue	-	-	-	-	-	326.6M	210.76M	256.58M	-
Product Revenue Growth	-	-	-	-	-	-	-35.47%	21.74%	-
Other	-	-	-	-	-	-	282K	664K	-
Other Growth	-	-	-	-	-	-	-	135.46%	-
License And Service	-	-	-	-	-	-	-	-	-
License And Service Growth	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2016	2017	2019	2021	2022	2023	2024
UNITED STATES	-	-	188.29M	-	356.07M	-	-	-	-
UNITED STATES Growth	-	-	-	-	-	-	-	-	-
Non Us	-	2.24M	1.81M	1.56M	-	-	-	-	-
Non Us Growth	-	-	-18.98%	-14.22%	-	-	-	-	-
U S	28.48M	27.8M	-	-	-	-	-	-	-
U S Growth	-	-2.38%	-	-	-	-	-	-	-
Foreign Countries	2.63M	-	-	-	-	-	-	-	-
Foreign Countries Growth	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Coherus Oncology, Inc. (CHRS) has a price-to-earnings (P/E) ratio of 6.6x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Coherus Oncology, Inc. (CHRS) reported $83.6M in revenue for fiscal year 2024. This represents a 4301% increase from $1.9M in 2012.

Coherus Oncology, Inc. (CHRS) grew revenue by 3.8% over the past year. Growth has been modest.

Yes, Coherus Oncology, Inc. (CHRS) is profitable, generating $155.0M in net income for fiscal year 2024 (10.7% net margin).

Dividend & Returns

Coherus Oncology, Inc. (CHRS) had negative free cash flow of $90.2M in fiscal year 2024, likely due to heavy capital investments.